ArticleJournal of circulating biomarkers
Secretory versus non-secretory hepatocellular carcinoma: associations of serum AFP, CEA and CA19-9 levels with clinical presentation, metastatic patterns, and survival.
Article in Journal of circulating biomarkers. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hepatocellular carcinoma (HCC) is a global health challenge, with disproportionately high mortality rates in low- and middle-income countries (LMICs). Tumor markers such as alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), and carbohydrate antigen 19-9 (CA19-9) are used for diagnostic purposes and for monitoring treatment results. The relationship between these markers, individually or in combination, with clinical presentation, metastatic patterns and survival outcomes has not been extensively researched. Methods: In this South African retrospective study, we assess the association of the tumor marker levels on presentation, diagnosis, and prognosis. Data was analyzed using chi-square tests, t-tests, and Kaplan-Meier survival analysis. Results: The study included 501 patients, treated between 2010 and 2024. Elevated AFP levels were associated with chronic hepatitis B virus (HBV) infection, hepatomegaly, and pulmonary metastases, while elevated CA19-9 levels were associated with more advanced liver disease. Survival analysis confirmed shorter survival for patients with elevated AFP and CA19-9 levels compared to normal levels (p < 0.001). Elevated CEA levels were not significantly associated with survival. Patients with no elevated markers (i.e., "triple-negative" for AFP, CEA, and CA19-9) had the longest survival, compared to those with multiple elevated markers (p < 0.001). Conclusion: AFP and CA19-9 elevations were associated with more advanced disease and poorer survival outcomes. We emphasize the importance of integrating tumor marker levels with imaging and histopathology for a multimodal diagnostic approach. Further research is needed to validate these associations to better define the role of biomarkers in HCC management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.